ALDEYRA THERAPEUTICS, INC. Long-Term Debt, Maturity, Remainder of Fiscal Year
ALDEYRA THERAPEUTICS, INC. (ALDX) had Long-Term Debt, Maturity, Remainder of Fiscal Year of $292.50 thousand as of 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Notes › Commitment and Contingencies
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear · last filed 2024-11-07
- 2024-09-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $292.50K.
- 2022-12-31: Long-Term Debt, Maturity, Remainder of Fiscal Year $1.04M.
- 2021-12-31: Long-Term Debt, Maturity, Remainder of Fiscal Year $0.00.
- 2020-12-31: Long-Term Debt, Maturity, Remainder of Fiscal Year $0.00; Long-Term Debt, Maturity, Remainder of Fiscal Year as first filed $3.66M.
| Period end | Long-Term Debt, Maturity, Remainder of Fiscal Year | Long-Term Debt, Maturity, Remainder of Fiscal Year as first filed |
|---|---|---|
| 2024-09-30 | $292.50K 10-Q · filed 2024-11-07 | |
| 2022-12-31 | $1.04M 10-Q · filed 2023-11-03 | |
| 2021-12-31 | $0.00 10-Q · filed 2022-11-10 | |
| 2020-12-31 | $0.00 10-Q · filed 2021-10-28 | $3.66M 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |